Literature DB >> 23319256

Intensity-modulated radiotherapy vs. parotid-sparing 3D conformal radiotherapy. Effect on outcome and toxicity in locally advanced head and neck cancer.

M Lambrecht1, D Nevens, S Nuyts.   

Abstract

BACKGROUND AND
PURPOSE: Intensity-modulated radiotherapy (IMRT) has rapidly become standard of care in the management of locally advanced head and neck squamous cell carcinoma (HNSCC). In this study, our aim was to retrospectively investigate the effect of the introducing IMRT on outcome and treatment-related toxicity compared to parotid-sparing 3D conformal radiotherapy (3DCRT).
MATERIAL AND METHODS: A total of 245 patients with stage III and IV HNSCC treated with primary radiotherapy between January 2003 and December 2010 were included in this analysis: 135 patients were treated with 3DCRT, 110 patients with IMRT. Groups were compared for acute and late toxicity, locoregional control (LRC), and overall survival (OS). Oncologic outcomes were estimated using Kaplan-Meier analysis and compared using a log-rank test. Acute toxicity was analyzed according to the Common Terminology Criteria for Adverse Events v3.0 and late toxicity was scored using the RTOG/EORTC late toxicity scoring system.
RESULTS: Median follow-up was 35 months in the IMRT group and 68 months in the 3DCRT group. No significant differences were found in 3-year LRC and OS rates between the IMRT group and 3DCRT group. Significantly less acute mucositis ≥ grade 3 was observed in the IMRT group (32% vs. 44%, p = 0.03). There was significantly less late xerostomia ≥ grade 2 in the IMRT group than in the 3DCRT group (23% vs. 68%, p < 0.001). After 24 months, there was less dysphagia ≥ grade 2 in the IMRT group although differences failed to reach statistical significance.
CONCLUSION: The introduction of IMRT in the radiotherapeutic management of locally advanced head and neck cancer significantly improved late toxicity without compromising tumor control compared to a parotid-sparing 3D conformal radiotherapy technique.

Entities:  

Mesh:

Year:  2013        PMID: 23319256     DOI: 10.1007/s00066-012-0289-7

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  23 in total

1.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

Authors:  J P Pignon; J Bourhis; C Domenge; L Designé
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

2.  CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines.

Authors:  Vincent Grégoire; Peter Levendag; Kian K Ang; Jacques Bernier; Marijel Braaksma; Volker Budach; Cliff Chao; Emmanuel Coche; Jay S Cooper; Guy Cosnard; Avraham Eisbruch; Samy El-Sayed; Bahman Emami; Cai Grau; Marc Hamoir; Nancy Lee; Philippe Maingon; Karin Muller; Hervé Reychler
Journal:  Radiother Oncol       Date:  2003-12       Impact factor: 6.280

3.  Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck.

Authors:  Vincent Grégoire; Avraham Eisbruch; Marc Hamoir; Peter Levendag
Journal:  Radiother Oncol       Date:  2006-04-17       Impact factor: 6.280

4.  Improved dosimetric and clinical outcomes with intensity-modulated radiotherapy for head-and-neck cancer of unknown primary origin.

Authors:  Allen M Chen; Bao-Qing Li; D Gregory Farwell; Joseph Marsano; Srinivasan Vijayakumar; James A Purdy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-24       Impact factor: 7.038

5.  Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy.

Authors:  Johannes A Langendijk; Patricia Doornaert; Irma M Verdonck-de Leeuw; Charles R Leemans; Neil K Aaronson; Ben J Slotman
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

Review 6.  Intensity-modulated radiation therapy for head and neck cancer: emphasis on the selection and delineation of the targets.

Authors:  Avraham Eisbruch; Robert L Foote; Brian O'Sullivan; Jonathan J Beitler; Bhadrasain Vikram
Journal:  Semin Radiat Oncol       Date:  2002-07       Impact factor: 5.934

7.  Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program.

Authors:  Marije R Vergeer; Patricia A H Doornaert; Derek H F Rietveld; C René Leemans; Ben J Slotman; Johannes A Langendijk
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-12-26       Impact factor: 7.038

Review 8.  Prevention and treatment of the consequences of head and neck radiotherapy.

Authors:  A Vissink; F R Burlage; F K L Spijkervet; J Jansma; R P Coppes
Journal:  Crit Rev Oral Biol Med       Date:  2003

9.  Dysphagia after chemoradiotherapy for head-and-neck squamous cell carcinoma: dose-effect relationships for the swallowing structures.

Authors:  Piet Dirix; Sarah Abbeel; Bianca Vanstraelen; Robert Hermans; Sandra Nuyts
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-06-24       Impact factor: 7.038

10.  Preservation of parotid function with uncomplicated conformal radiotherapy.

Authors:  Annelies Maes; Caroline Weltens; Patrick Flamen; Philippe Lambin; Ria Bogaerts; Xuan Liu; Jan Baetens; Robert Hermans; Walter Van den Bogaert
Journal:  Radiother Oncol       Date:  2002-05       Impact factor: 6.280

View more
  17 in total

1.  Intensity-modulated radiotherapy for laryngeal and hypopharyngeal cancer: minimization of late dysphagia without jeopardizing tumor control.

Authors:  Anouchka Modesto; Anne Laprie; Laure Vieillevigne; Pierre Graff; Jérôme Sarini; Sébastien Vergez; Jean-Pierre Delord; Jean-Claude Farenc; Emmanuelle Vigarios; Thomas Filleron; Michel Rives
Journal:  Strahlenther Onkol       Date:  2014-11-01       Impact factor: 3.621

2.  New possibilities for volumetric-modulated arc therapy using the Agility™ 160-leaf multileaf collimator.

Authors:  Nadine Blümer; Christian Scherf; Janett Köhn; Eugen Kara; Britta Loutfi-Krauß; Detlef Imhoff; Claus Rödel; Ulla Ramm; Jörg Licher
Journal:  Strahlenther Onkol       Date:  2014-07-25       Impact factor: 3.621

3.  Lipiodol injections for optimization of target volume delineation in a patient with a second tumor of the oropharynx: A case report.

Authors:  Marlen Haderlein; Ricarda Merten; Andrea Stojanovic; Stefan Speer; Claudia Scherl; Rainer Fietkau; Oliver J Ott
Journal:  Strahlenther Onkol       Date:  2015-06-04       Impact factor: 3.621

4.  Analyzing the performance of the planning system by use of AAPM TG 119 test cases.

Authors:  L Nithya; N Arunai Nambi Raj; Sasikumar Rathinamuthu; Manish Bhushan Pandey
Journal:  Radiol Phys Technol       Date:  2015-07-04

5.  Parotid glands in whole-brain radiotherapy: 2D versus 3D technique for no sparing or sparing.

Authors:  Marianna Trignani; Domenico Genovesi; Annamaria Vinciguerra; Angelo Di Pilla; Antonietta Augurio; Monica Di Tommaso; Giampiero Ausili Cèfaro; Marta Di Nicola
Journal:  Radiol Med       Date:  2014-07-18       Impact factor: 3.469

6.  Toxicity Profile of IMRT Vs. 3D-CRT in Head and Neck Cancer: A Retrospective Study.

Authors:  Gopa Ghosh; Ramanjis Tallari; Anupam Malviya
Journal:  J Clin Diagn Res       Date:  2016-09-01

7.  8-prenylnaringenin and tamoxifen inhibit the shedding of irradiated epithelial cells and increase the latency period of radiation-induced oral mucositis : cell culture and murine model.

Authors:  Tine De Ryck; Annouchka Van Impe; Barbara W Vanhoecke; Arne Heyerick; Luc Vakaet; Wilfried De Neve; Doreen Müller; Margret Schmidt; Wolfgang Dörr; Marc E Bracke
Journal:  Strahlenther Onkol       Date:  2014-11-29       Impact factor: 3.621

8.  Postoperative chemoradiotherapy following pancreaticoduodenectomy. Impact of dose-volumetric parameters on the development of diabetes mellitus.

Authors:  K Eom; E K Chie; K Kim; J J Jang; S W Kim; D Y Oh; S A Im; T Y Kim; Y J Bang; S W Ha
Journal:  Strahlenther Onkol       Date:  2013-08-03       Impact factor: 3.621

9.  Taxane-containing induction chemotherapy followed by definitive chemoradiotherapy. Outcome in patients with locally advanced head and neck cancer.

Authors:  J O Brömme; M Schmücking; A Arnold; R Giger; D Rauch; D Leiser; L Plasswilm; A Geretschläger; P Ghadjar; D M Aebersold
Journal:  Strahlenther Onkol       Date:  2013-07-04       Impact factor: 3.621

10.  Clinical factors impacting on late dysphagia following radiotherapy in patients with head and neck cancer.

Authors:  Sarah Deschuymer; Daan Nevens; Fréderic Duprez; Annouschka Laenen; Eddy Dejaeger; Wilfried De Neve; Ann Goeleven; Sandra Nuyts
Journal:  Br J Radiol       Date:  2018-05-23       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.